MétaCan
Menu
Back to cohort
Record W4311735609 · doi:10.1093/ofid/ofac492.638

586. Systematic Literature Review of the 13-valent Pneumococcal Conjugate Vaccine (PCV13) Effectiveness Against Invasive Pneumococcal Disease in Children Globally

2022· article· en· W4311735609 on OpenAlexaff
Johnna Perdrizet, Iwona Pustułka, Carol Forbes, Emily K. Horn, Bradford D. Gessner, Kyla Hayford

Bibliographic record

VenueOpen Forum Infectious Diseases · 2022
Typearticle
Languageen
FieldMedicine
TopicPneumonia and Respiratory Infections
Canadian institutionsPfizer (Canada)
Fundersnot available
KeywordsMedicinePneumococcal conjugate vaccinePneumococcal diseaseVaccinationPediatricsCochrane LibraryObservational studySystematic reviewStreptococcus pneumoniaeMEDLINEMeta-analysisInternal medicineImmunology

Abstract

fetched live from OpenAlex

Abstract Background After a decade of 13-valent pneumococcal conjugate vaccine (PCV13) use in children, many observational studies have evaluated PCV13 vaccine effectiveness (VE) in various epidemiologic and geographic settings. The objective of this study was to systematically review the global evidence on VE of PCV13 against IPD in children. Methods A systematic literature review using Cochrane methods was conducted in November 2021 to evaluate PCV13 VE against vaccine-type and serotype-specific IPD in children. A search of Medline, Embase, the Cochrane Library (CENTRAL and CDSR), and 5 key conferences (2019-2021) was conducted, and eligible English-language articles were abstracted. Results 15 studies on PCV13 VE were included, primarily from Europe (n=7) and North America (n=3) as well as Africa (n=2), Australasia (n=2), and Asia (n=1). 11 reported VE in children who completed the full vaccination schedule [3+1 (n=3), 2+1 (n=4), 3+0 (n=3), and mixed 3+1 or 2+1 schedules (n=1)] (Table 1). 4 studies did not report VE after the complete vaccination schedule. 8 studies reported PCV13-type VE, 3 reported PCV7-type VE, and 6 reported PCV13 non-PCV7 VE. PCV13-type VE was 90 and 91% in studies using a 3+1 schedule (n=2), 76% and 79% in studies using a 2+1 schedule (n=2) and ranged from 59% to 94% in a 3+0 schedule (n=3), with variability by study design and age range (Table 1). One study reported 100% PCV13-type VE in Spain where mixed 3+1 and 2+1 schedules were used. All PCV13-type VE results were statistically significant except two outcomes restricted to children 12-24 month of age from a single study in Australia. High VE was reported against PCV13 non-PCV7 serotype IPD for fully vaccinated children across all schedules, ranging from 60% to 100% (n=6). PCV13 was effective against the shared PCV7 serotypes, ranging from 75% to 83% (n=3). Conclusion Children fully vaccinated with PCV13 have a high level of direct protection against vaccine-type IPD, irrespective of geographic variation. PCV13 VE against the shared PCV7 serotypes remained high and PCV13 VE was also high for the 6 additional PCV13-non PCV7 serotypes. PCV13 VE tended to be higher in 3+1 schedules and additional analyses by dosing schedule are needed. Disclosures Johnna Perdrizet, MPH, Pfizer Inc: Employee|Pfizer Inc: Stocks/Bonds Iwona Pustulka, MSc, Pfizer Inc.: I'm an employee of Evidera who have been paid by Pfizer Inc. to conduct an SLR which results are presented in the abstract Carol A. Forbes, PhD, Evidera (part of Thermo Fisher Scientific): Employee|Pfizer Inc: I am an employee of Evidera (part of Thermo Fisher Scientific)who have been paid by Pfizer Inc. to carry out the work reported in this abstract|Thermo Fisher Scientific: Stocks/Bonds Emily Horn, MSc, Pfizer Inc: Employee Bradford D. Gessner, M.D., M.P.H., Pfizer Inc.: Employee|Pfizer Inc.: Stocks/Bonds Kyla hayford, PhD, Pfizer Vaccines: Employed|Pfizer Vaccines: Stocks/Bonds.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.036
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.002
Science and technology studies0.0010.000
Scholarly communication0.0000.000
Open science0.0010.001
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.006
GPT teacher head0.259
Teacher spread0.254 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueOpen Forum Infectious DiseasesSame topicPneumonia and Respiratory InfectionsFrench-language works237,207